Skip to content Skip to sidebar Skip to footer

GSK ai News

PathAI taps AI pathology tool for GSK NASH trial

PathAI is partnering with GSK on a randomised Phase IIb trial in non-alcoholic steatohepatitis (NASH). The Boston based artificial intelligence (AI)-powered pathology company will be responsible for generating, digitising, and analysing liver biopsy slides for central pathologist evaluation. In addition, its AI-based Measurement of NASH Histology (AIM-NASH) tool will be used for histological evaluation. The…

Read More

PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial

Part of Multi-year Partnership Focusing on Drug Development in NASH and Oncology  BOSTON , March 30, 2023 /PRNewswire/ -- PathAI, a leading provider of AI-powered pathology, today announced its partnership with GSK (LSE/NYSE: GSK) on HORIZON, a randomized Phase 2b non-alcoholic steatohepatitis (NASH) clinical trial (NCT05583344). The trial will measure improvements in…

Read More